Manatuck Hill Partners LLC bought a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 100,000 shares of the company's stock, valued at approximately $486,000. Manatuck Hill Partners LLC owned approximately 0.54% of OptimizeRx as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in the company. Barclays PLC boosted its stake in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company's stock valued at $208,000 after purchasing an additional 21,060 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of OptimizeRx during the fourth quarter valued at $51,000. Greenwood Capital Associates LLC increased its holdings in OptimizeRx by 31.5% in the 4th quarter. Greenwood Capital Associates LLC now owns 88,596 shares of the company's stock worth $431,000 after buying an additional 21,240 shares in the last quarter. AMH Equity Ltd raised its position in OptimizeRx by 25.0% in the 4th quarter. AMH Equity Ltd now owns 125,000 shares of the company's stock worth $608,000 after buying an additional 25,000 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in OptimizeRx during the 4th quarter valued at about $25,000. Hedge funds and other institutional investors own 76.47% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently commented on OPRX shares. B. Riley upgraded shares of OptimizeRx to a "strong-buy" rating in a research note on Wednesday, March 12th. Royal Bank of Canada reiterated a "sector perform" rating and set a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Finally, JMP Securities reissued a "market outperform" rating and set a $8.00 price target on shares of OptimizeRx in a report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $9.06.
Check Out Our Latest Stock Report on OptimizeRx
Insider Transactions at OptimizeRx
In other news, Director James Paul Lang bought 321,408 shares of OptimizeRx stock in a transaction that occurred on Friday, March 14th. The stock was bought at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the acquisition, the director now owns 389,452 shares of the company's stock, valued at $2,959,835.20. The trade was a 472.35 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.10% of the company's stock.
OptimizeRx Stock Performance
OptimizeRx stock traded up $0.41 during trading on Friday, reaching $10.05. The company had a trading volume of 223,791 shares, compared to its average volume of 268,257. The firm has a market capitalization of $185.85 million, a price-to-earnings ratio of -7.56 and a beta of 1.28. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm's 50-day simple moving average is $7.69 and its 200 day simple moving average is $6.18. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $14.13.
OptimizeRx Profile
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
See Also
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
